Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection

Antiviral Research

Volumn 83, Issue 3, 2009, Pages 207-213

  James, Scott H ^a   Kimberlin, David W ^a   Whitley, Richard J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Herpesvirus central nervous system; Neonatal herpes simplex virus infection

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BAY 57 1293; BENZIMIDAVIR; CIDOFOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS VACCINE; DNA; DNA POLYMERASE; ENZYME INHIBITOR; FOSCARNET; GANCICLOVIR; GW 1263W94; GW 275175X; HEXADECYLOXYPROPYL CIDOFOVIR; IDOXURIDINE; OCTADECYLOXYETHYL CIDOFOVIR; PLACEBO; RECOMBINANT BETA INTERFERON; THYMIDINE KINASE; TOMEGLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIDARABINE; VIRUS DNA;

ADJUVANT THERAPY; ANTIVIRAL RESISTANCE; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA CLEAVAGE; DNA DETERMINATION; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITION; EVOKED BRAIN STEM AUDITORY RESPONSE; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HUMAN; IMMUNE DEFICIENCY; INHIBITION KINETICS; MORBIDITY; MORTALITY; MUTAGENICITY; NEUROPROTECTION; NEUTROPENIA; NEWBORN INFECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINATAL PERIOD; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

ADULT; CHILD; CYTOMEGALOVIRUS INFECTIONS; ENCEPHALITIS, HERPES SIMPLEX; HERPES SIMPLEX; HUMANS;

CYTOMEGALOVIRUS; HERPES; HERPESVIRIDAE; SIMPLEXVIRUS;

EID: 68249118501     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.04.010     Document Type: Review

References (73)

1. Bauer P.W., Parizi-Robinson M., Roland P.S., and Yegappan S. Cytomegalovirus in the perilymphatic fluid. Laryngoscope 115 (2005) 223-225
2. Beadle J.R., Hartline C., Aldern K.A., Rodriguez N., Harden E., Kern E.R., and Hostetler K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46 (2002) 2381-2386
3. Betz U.A., Fischer R., Kleymann G., Hendrix M., and Rubsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46 (2002) 1766-1772
4. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
5. Boston Interhospital Virus Study Group. An NIAID-sponsored cooperative antiviral clinical study: failure of high dose 5-iodo-2′-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity. NEJM 292 (1975) 599-603
6. Brasfield D.M., Stagno S., Whitley R.J., Cloud G., Cassell G., and Tiller R.E. Infant pneumonitis associated with cytomegalovirus, chlamydia, pneumocystis, and ureaplasma. Pediatrics 79 (1987) 76-83
7. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., and Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 289 (2003) 203-209
8. Buerger I., Reefschlaeger J., Bender W., Eckenberg P., Popp A., Weber O., Graeper S., Klenk H.D., Ruebsamen-Waigmann H., and Hallenberger S. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75 (2001) 9077-9086
9. Cheeran M.C., Lokensgard J.R., and Schleiss M.R. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev. 22 (2009) 99-126 (Table of Contents)
10. Chou S., and Marousek G.I. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 50 (2006) 3470-3472
11. Christophers J., Clayton J., Craske J., Ward R., Collins P., Trowbridge M., and Darby G. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob. Agents Chemother. 42 (1998) 868-872
12. Ciesla S.L., Trahan J., Wan W.B., Beadle J.R., Aldern K.A., Painter G.R., and Hostetler K.Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59 (2003) 163-171
13. Conboy T.J., Pass R.F., Stagno S., Alford C.A., Myers G.J., Britt W.J., McCollister F.P., Summers M.N., McFarland C.E., and Boll T.J. Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J. Pediatr. 111 (1987) 343-348
14. Dahle A.J., Fowler K.B., Wright J.D., Boppana S.B., Britt W.J., and Pass R.F. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J. Am. Acad. Aud. 11 (2000) 283-290
15. Davis L.E., Johnsson L.G., and Kornfeld M. Cytomegalovirus labyrinthitis in an infant: morphological, virological, and immunofluorescent studies. J. Neuropathol. Exp. Neurol. 40 (1981) 9-19
16. Demmler G.J. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev. Infect. Dis. 13 (1991) 315-329
17. Dollard S.C., Grosse S.D., and Ross D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. (2007)
18. Evers D.L., Komazin G., Shin D., Hwang D.D., Townsend L.B., and Drach J.C. Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Res. 56 (2002) 61-72
19. Fonseca-Aten M., Messina A.F., Jafri H.S., and Sanchez P.J. Herpes simplex virus encephalitis during suppressive therapy with acyclovir in a premature infant. Pediatrics 115 (2005) 804-809
20. Gilbert C., Bestman-Smith J., and Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Update 5 (2002) 88-114
21. Gilbert C., and Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49 (2005) 873-883
22. Granstrom M.L., and Leinikki P. Illnesses during the first two years of life and their association with perinatal cytomegalovirus infection. Scand. J. Infect. Dis. 10 (1978) 257-264
23. Griffiths P.D., and Emery V.C. Cytomegalovirus. In: Richman D.D., Whitley R.J., and Hayden F.G. (Eds). Clinical Virology (2002), ASM Press, Washington, DC 433-461
24. Griffiths P.D., and McLaughlin J.E. Cytomegalovirus. In: Scheld W.M., Whitley R.J., and Marra C.M. (Eds). Infections of the Central Nervous System (2004), Lippincott Williams & Wilkins, Philadelphia 159-173
25. Hutto C., Arvin A., Jacobs R., Steele R., Stagno S., Lyrene R., Willett L., Powell D., Andersen R., and Werthammer J. Intrauterine herpes simplex virus infections. J. Pediatr. 110 (1987) 97-101
26. Istas A.S., Demmler G.J., Dobbins J.G., and Stewart J.A. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin. Infect. Dis. 20 (1995) 665-670
27. Jabs D.A., Enger C., Dunn J.P., and Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J. Infect. Dis. 177 (1998) 770-773
28. Johnson R.T., Olson L.C., and Buescher E.L. Herpes simplex virus infections of the nervous system: problems in laboratory diagnosis. Arch. Neurol. 18 (1968) 260-264
29. Kamei S., Sekizawa T., Shiota H., Mizutani T., Itoyama Y., Takasu T., Morishima T., and Hirayanagi K. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J. Neurol. Neurosurg. Psychol. 76 (2005) 1544-1549
30. Kimberlin D.W. Management of HSV encephalitis in adults and neonates: diagnosis, prognosis and treatment. Herpes 14 (2007) 11-16
31. Kimberlin D.W., Acosta E.P., Sanchez P.J., Sood S., Agrawal V., Homans J., Jacobs R.F., Lang D., Romero J.R., Griffin J., Cloud G.A., Lakeman F.D., and Whitley R.J. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J. Infect. Dis. 197 (2008) 836-845
32. Kimberlin D.W., Lakeman F.D., Arvin A.M., Prober C.G., Corey L., Powell D.A., Burchett S.K., Jacobs R.F., Starr S.E., Whitley R.J., and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J. Infect. Dis. 174 (1996) 1162-1167
33. Kimberlin D.W., Lin C.Y., Jacobs R.F., Powell D.A., Corey L., Gruber W.C., Rathore M., Bradley J.S., Diaz P.S., Kumar M., Arvin A.M., Gutierrez K., Shelton M., Weiner L.B., Sleasman J.W., de Sierra T.M., Weller S., Soong S.J., Kiell J., Lakeman F.D., Whitley R.J., and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108 (2001) 230-238
34. Kimberlin D.W., Lin C.Y., Jacobs R.F., Powell D.A., Frenkel L.M., Gruber W.C., Rathore M., Bradley J.S., Diaz P.S., Kumar M., Arvin A.M., Gutierrez K., Shelton M., Weiner L.B., Sleasman J.W., de Sierra T.M., Soong S.J., Kiell J., Lakeman F.D., Whitley R.J., and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 108 (2001) 223-229
35. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., Jacobs R.F., Vaudry W., Pass R.F., Kiell J.M., Soong S.J., Whitley R.J., and the National Institute of Allergy Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143 (2003) 16-25
36. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J. Virol. 77 (2003) 11499-11506
37. Krosky P.M., Baek M.C., and Coen D.M. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77 (2003) 905-914
38. Maschmann J., Hamprecht K., Dietz K., Jahn G., and Speer C.P. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin. Infect. Dis. 33 (2001) 1998-2003
39. Mizrahi E.M., and Tharp B.R. A characteristic EEG pattern in neonatal herpes simplex encephalitis. Neurology 32 (1982) 1215-1220
40. Nahmias A.J., Lee F.K., and Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. 69 Supplement (1990) 19-36
41. Nahmias A.J., Whitley R.J., Visintine A.N., Takei Y., and Alford Jr. C.A. Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J. Infect. Dis. 145 (1982) 829-836
42. Noyola D.E., Demmler G.J., Williamson W.D., Griesser C., Sellers S., Llorente A., Littman T., Williams S., Jarrett L., and Yow M.D. Cytomegalovirus urinary excretion and long term outcome in children with congenital cytomegalovirus infection. Congenital CMV Longitudinal Study Group. Pediatr. Infect. Dis. 19 (2000) 505-510
43. Oliver, S., Cloud, G., Sánchez, P., Demmler, G., Dankner, W., Shelton, M., Jacobs, R., Vaudry, W., Pass, R., Soong, S., Whitley, R., Kimberlin, D., 2006. Effect of Ganciclovir (GCV) Therapy on Neurodevelopmental Outcomes in Symptomatic Congenital Cytomegalovirus (CMV) Infections Involving the Central Nervous System (CNS): A Randomized, Controlled Study. Society for Pediatric Research (SPR) Annual Meeting, Abstract # 752908.
44. Olson L.C., Buescher E.L., Artenstein M.S., and Parkman P.D. Herpesvirus infections of the human central nervous system. NEJM 277 (1967) 1271-1277
45. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., Corey L., Hill J., Davis E., Flanigan C., and Cloud G. Vaccine prevention of maternal cytomegalovirus infection. NEJM 360 (2009) 1191-1199
46. Peng T., Zhu J., Hwangbo Y., Corey L., and Bumgarner R.E. Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts. J. Virol. 82 (2008) 1934-1945
47. Puchhammer-Stockl E., Presterl E., Croy C., Aberle S., Popow-Kraupp T., Kundi M., Hofmann H., Wenninger U., and Godl I. Screening for possible failure of herpes simplex virus PCR in cerebrospinal fluid for the diagnosis of herpes simplex encephalitis. J. Med. Virol. 64 (2001) 531-536
48. Roizen N., Swisher C.N., Stein M.A., Hopkins J., Boyer K.M., Holfels E., Mets M.B., Stein L., Patel D., and Meier P. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 95 (1995) 11-20
49. Ross S.A., and Boppana S.B. Congenital cytomegalovirus infection: outcome and diagnosis. Semin. Pediatr. Infect. Dis. 16 (2005) 44-49
50. Sainio K., Granstrom M.L., Pettay O., and Donner M. EEG in neonatal herpes simplex encephalitis. Electroencephalogr. Clin. Neurophysiol. 56 (1983) 556-561
51. Schleiss M.R., and McVoy M.A. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Exp. Rev. Anti-Infect. Ther. 2 (2004) 389-403
52. Selleseth D.W., Talarico C.L., Miller T., Lutz M.W., Biron K.K., and Harvey R.J. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 47 (2003) 1468-1471
53. Sergerie Y., Boivin G., Gosselin D., and Rivest S. Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. J. Infect. Dis. 195 (2007) 817-825
54. Staras S.A., Dollard S.C., Radford K.W., Flanders W.D., Pass R.F., and Cannon M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin. Infect. Dis. 43 (2006) 1143-1151
55. Stranska R., Schuurman R., Nienhuis E., Goedegebuure I.W., Polman M., Weel J.F., Wertheim-Van Dillen P.M., Berkhout R.J., and van Loon A.M. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J. Clin. Virol. 32 (2005) 7-18
56. Strauss M. Human cytomegalovirus labyrinthitis. Am. J. Otolaryngol. 11 (1990) 292-298
57. Sugiura S., Nishiyama Y., Morishita Y., Sato E., Beppu R., Hattori T., and Nakashima T. Detection of herpesvirus DNAs in perilymph obtained from patients with sensorineural hearing loss by real-time polymerase chain reaction. Laryngoscope 114 (2004) 2235-2238
58. Taylor J.L., Tom P., and O'Brien W.J. Combined effects of interferon-alpha and acyclovir on herpes simplex virus type 1 DNA polymerase and alkaline DNase. Antiviral Res. 38 (1998) 95-106
59. Underwood M.R., Ferris R.G., Selleseth D.W., Davis M.G., Drach J.C., Townsend L.B., Biron K.K., and Boyd F.L. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob. Agents Chemother. 48 (2004) 1647-1651
60. Whitley R., Arvin A., Prober C., Burchett S., Corey L., Powell D., Plotkin S., Starr S., Alford C., Connor J., and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral study Group. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. NEJM 324 (1991) 444-449
61. Whitley R.J. Herpes simplex virus infections. In: Remington J.S., and Klein J.O. (Eds). Infectious Diseases of the Fetus and Newborn Infants (1990), W.B. Saunders Company, Philadelphia 282-305
62. Whitley R.J. Herpes simplex virus. In: Scheld M.W., Whitley R.J., and Marra C.M. (Eds). Infections in the Central Nervous System (2004), Lippincott Williams & Wilkins, Philadelphia 123-144
63. Whitley R.J., Alford C.A., Hirsch M.S., Schooley R.T., Luby J.P., Aoki F.Y., Hanley D., Nahmias A.J., and Soong S.J. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. NEJM 314 (1986) 144-149
64. Whitley R.J., Cobbs C.G., Alford Jr. C.A., Soong S.J., Hirsch M.S., Connor J.D., Corey L., Hanley D.F., Levin M., and Powell D.A. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAID Collaborative Antiviral Study Group. JAMA 262 (1989) 234-239
65. Whitley R.J., Corey L., Arvin A., Lakeman F.D., Sumaya C.V., Wright P.F., Dunkle L.M., Steele R.W., Soong S.J., and Nahmias A.J. Changing presentation of herpes simplex virus infection in neonates. J. Infect. Dis. 158 (1988) 109-116
66. Whitley R.J., Nahmias A.J., Soong S.J., Galasso G.G., Fleming C.L., and Alford C.A. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 66 (1980) 495-501
67. Whitley R.J., and Roizman B. Herpes simplex virus infections. Lancet 357 (2001) 1513-1518
68. Whitley R.J., and Roizman B. Herpes simplex viruses. In: Richman D.D., Whitley R.J., and Hayden F.G. (Eds). Clinical Virology (2004), ASM Press, Washington, DC 375-401
69. Whitley R.J., Soong S.J., Linneman Jr. C., Liu C., Pazin G., and Alford C.A. Herpes simplex encephalitis. Clinical assessment. JAMA 247 (1982) 317-320
70. Wintergerst U., Kugler K., Harms F., Belohradsky B.H., and Pfluger T. Therapy of focal viral encephalitis in children with aciclovir and recombinant beta-interferon-results of a placebo-controlled multicenter study. Eur. J. Med. Res. 10 (2005) 527-531
71. Woolf N.K., Ochi J.W., Silva E.J., Sharp P.A., Harris J.P., and Richman D.D. Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob. Agents Chemother. 32 (1988) 865-872
72. Xu F., Lee F.K., Morrow R.A., Sternberg M.R., Luther K.E., Dubin G., and Markowitz L.E. Seroprevalence of herpes simplex virus type 1 in children in the United States. J. Pediatr. 151 (2007) 374-377
73. Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., Berman S.M., and Markowitz L.E. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296 (2006) 964-973